Rx Item-Paclitaxel 6Mg/Ml Vial 50Ml By Wg Critical Care

Item info. These highlights do not include all the info. needed to use ABRAXANE safely and effectively. See full prescribing info. for ABRAXANE ABRAXANE for Injectable Suspension (paclitaxel protein -bound particles for injectable suspension) (albumin- bound) Initial U.S. Approval: 2005 WARNING NEUTROPENIA See full prescribing info. for complete boxed warning. Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm . It is recommended that frequent peripheral blood cell counts be performed to monitor the occurrence of bone marrow suppression. (4, 5.1, 6.1, 6.2 6.3 DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS RECENT MAJOR CHANGES - Dosage and Administration 2.4 2.8 12/2014 Dosage and Administration 07/2015 Warnings and Precautions, Hepatic Impairment 12/2014 - INDICATIONS AND USAGE - ABRAXANE is microtubule inhibitor indicated for the treatment of ? Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unl ess clinically contraindicated. Locally advanced or metastatic non -small cell lung cancer (NSCLC) as first -line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Metastatic adenocarcinoma of the ancreas as first -line treatment in combination with gemcitabine. DOSAGE AND ADMINISTRATION -- Metastatic Breast Cancer: Recommended dosage of ABRAXANE is 260 mg/ 2 intravenous ly over 30 min ute every weeks Non -Small Cell Lung Cancer: Recommended dosage of ABRAXANE is 100 mg/m intravenous ly over 30 minutes on Days 1, 8, and 15 of each 21- day cycle; administer carboplatin on Day of each 21- day cycle immediately after ABRAXANE Adenocarcinoma of the Pancreas: Recommended dosage of ABRAXANE is 125 mg/m intravenously over 30- 40 minutes on Days 1, and 15 of each 28- day cycle administer gemcitabine on Days 1, and 15 of each 28- day cycle immediately after ABRAXANE Do not administer ABRAXANE to any patient with AST 10 ULN or bilirubin 5 ULN. Do not administer ABRAXANE to patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For diseases other than metastatic adenocarcinoma of the pancreas reduce starting dose in patients with moderate to severe hepatic impairment. (2. 4) Dose Reductions: Dose reductions or discontinuation may be needed based on severe hematologic neurologic cutaneous, or gastrointestinal toxicities (2. 5) Use caution when handling cytotoxic drugs. Closely monitor the infusion site for extravasation and infiltration. No premedication is required prior to administration. (2. 6) DOSAGE FORMS AND STRENGTHS ? For injectable suspension: lyophilized powder containing 100 mg of paclitaxel formulated as albumin- bound particles in single- use vial for reconstitution.

RX ITEM-Paclitaxel 6Mg/Ml Vial 50Ml By W
NDC 44567-0506-01 UPC/GTIN No.3-44567-50601-9 Mfg.Part No.50601

Paclitaxel 6Mg/Ml Vial 50Ml By Wg Critic
BRAND: PACLITAXEL NDC: 44567-0506-01,44567050601 UPC: 3-44567-50601-9,344567506019

Click above for Abraxane
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.